• David H Molyneux, Lorenzo Savioli, and Dirk Engels.
• Department of Parasitology, Liverpool School of Tropical Medicine, Liverpool, UK. Electronic address: david.molyneux@lstmed.ac.uk.
• Lancet. 2017 Jan 21; 389 (10066): 312-325.

AbstractThe concept of neglected tropical diseases (NTDs) emerged more than a decade ago and has been recognised as a valid way to categorise diseases that affect the poorest individuals. Substantial progress in control and elimination has been achieved and policy momentum has been generated through continued bilateral, philanthropic, and non-governmental development organisation (NGDO) support, and donations of drugs from pharmaceutical companies. WHO has defined a Roadmap to reach 2020 targets, which was endorsed by member states in a World Health Assembly Resolution in 2013. NTDs have been included within the Sustainable Development Goal targets and are a crucial component of universal health coverage, conceptualised as "leaving no one behind". WHO reported that more than 1 billion people in 88 countries have benefited from preventive chemotherapy in 2014. The research agenda has defined the need for affordable products (diagnostics, drugs and insecticides). However challenges such as insecurity and weak health systems continue to prevail in the poorest countries, inhibiting progress in scaling up and also in achieving Roadmap goals.Copyright © 2017 Elsevier Ltd. All rights reserved.

11 keywords...

hide…